Provenance history of a Late Triassic-Jurassic Gondwana margin forearc basin, Murihiku Terrane, North Island, New Zealand: petrographic and geochemical constraints

The Murihiku Terrane in the North Island was a forearc basin adjacent to a volcanic arc along the eastern margin of Gondwana during the Mesozoic. The rocks that infill the basin are mainly volcaniclastic sandstones and mudstones, often turbiditic, with sparse shellbeds, rhyolitic tuffs, carbonaceous sandstones, plant beds, concretionary horizons, and rare thick granitoid-rich conglomerates. Petrographic studies of the rock fragments in the sandstones show that andesites are the dominant lithic type, but there is a wide range of other lithologies, including dacites, rhyolites, ignimbrites, granitoids, quartzofeldspathic mica schists, rare amphibolites, and reworked mudstones and sandstones. The sandstones are texturally and mineralogically immature and suggest deposition relatively close to a source of high relief, undergoing physical rather than chemical weathering in cool- to cold-temperate conditions. Geochemical analyses of 67 whole-rock volcaniclastic sandstones and siltstones indicate that they were derived from an active and dissected volcanic arc in a convergent margin setting built upon relatively thin continental crust. Modal petrographic data and whole-rock geochemistry both confirm that there were systematic variations with time in the composition of clastic material being supplied to the basin. From the Late Triassic to Middle Jurassic, there was a decrease in silicic volcanic material, plutonics, and metamorphics, and an increase in the supply of andesitic detritus. This was followed in the Late Jurassic by a broader range of volcanic detritus, varying from basaltic andesite to rhyolite, which may have been caused by progressive extension of the volcanic arc and thinning of the crust, a precursor to the breakup of Gondwana in the Early-Middle Cretaceous. Comparison with the Southland segment of the Murihiku Terrane in the South Island suggests that there were significant along-arc source variations, with relatively less silicic but greater andesitic and continental crust contributions in the North Island than in Southland. This may be analogous to the modern Taupo-Kermadec arc where there is a south-north along-arc transition from a continental to an oceanic arc

The formulation and implementation of British agricultural policy 1945-1951.

SIGLEAvailable from British Library Document Supply Centre- DSC:DX174557 / BLDSC - British Library Document Supply CentreGBUnited Kingdo

New dynamics in cerebellar Purkinje cells: torus canards

We describe a transition from bursting to rapid spiking in a reduced mathematical model of a cerebellar Purkinje cell. We perform a slow-fast analysis of the system and find that -- after a saddle node bifurcation of limit cycles -- the full model dynamics follow temporarily a repelling branch of limit cycles. We propose that the system exhibits a dynamical phenomenon new to realistic, biophysical applications: torus canards.Comment: 4 pages; 4 figures (low resolution); updated following peer-review: language and definitions updated, Figures 1 and 4 updated, typos corrected, references added and remove

Evidence of a large seasonal coastal upwelling system along the southern shelf of Australia

2000 FLORIDA AVE NW, WASHINGTON, USA, DC, 2000

A randomised controlled trial of a digital intervention (Renewed) to support symptom management, wellbeing and quality of life in cancer survivors

Background: Many cancer survivors following primary treatment have prolonged poor quality of life.Aim: To determine the effectiveness of a bespoke digital intervention to support cancer survivors.Design: Pragmatic parallel open randomised trial.Setting: UK general practices.Methods: People having finished primary treatment (&lt;= 10 years previously) for colo-rectal, breast or prostate cancers, with European-Organization-for-Research-and-Treatment-of-Cancer QLQ-C30 score &lt;85, were randomised by online software to: 1) detailed ‘generic’ digital NHS support (‘LiveWell’;n=906), 2) a bespoke complex digital intervention (‘Renewed’;n=903) addressing symptom management, physical activity, diet, weight loss, distress, or 3) ‘Renewed-with-support’ (n=903): ‘Renewed’ with additional brief email and telephone support. Results: Mixed linear regression provided estimates of the differences between each intervention group and generic advice: at 6 months (primary time point: n’s respectively 806;749;705) all groups improved, with no significant between-group differences for EORTC QLQ-C30, but global health improved more in both intervention groups. By 12 months there were: small improvements in EORTC QLQ-C30 for Renewed-with-support (versus generic advice: 1.42, 95% CIs 0.33-2.51); both groups improved global health (12 months: renewed: 3.06, 1.39-4.74; renewed-with-support: 2.78, 1.08-4.48), dyspnoea, constipation, and enablement, and lower NHS costs (generic advice £265: in comparison respectively £141 (153-128) and £77 (90-65) lower); and for Renewed-with-support improvement in several other symptom subscales. No harms were identified.Conclusion: Cancer survivors quality of life improved with detailed generic online support. Robustly developed bespoke digital support provides limited additional short term benefit, but additional longer term improvement in global healthenablement and symptom management, with substantially lower NHS costs.<br/

A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates

Sorafenib monotherapy in patients with metastatic melanoma was explored in this multi-institutional phase II study. In correlative studies the impact of sorafenib on cyclin D1 and Ki67 was assessed. mutational status and clinical activity. No significant changes in expression of cyclin D1 or Ki67 with sorafenib treatment were demonstrable in the 15 patients with pre-and post-treatment tumor samples. mutational status of the tumor was not associated with clinical activity and no significant effect of sorafenib on cyclin D1 or Ki67 was seen, suggesting that sorafenib is not an effective BRAF inhibitor or that additional signaling pathways are equally important in the patients who benefit from sorafenib